injury may result in the development of epilepsy, one of the most common neurological disorders. We previously demonstrated that albumin is critical in the generation of epilepsy after blood-brain barrier (BBB) compromise. Here, we identify TGF-β pathway activation as the underlying mechanism. We demonstrate that direct activation of the TGF-β pathway by TGF-β1 results in epileptiform activity similar to that after exposure to albumin. Coimmunoprecipitation revealed binding of albumin to TGF-β receptor II, and Smad2 phosphorylation confirmed downstream activation of this pathway. Transcriptome profiling demonstrated similar expression patterns after BBB breakdown, albumin, and TGF-β1 exposure, including modulation of genes associated with the TGF-β pathway, early astrocytic activation, inflammation, and reduced inhibitory transmission. Importantly, TGF-β pathway blockers suppressed most albumin-induced transcriptional changes and prevented the generation of epileptiform activity. Our present data identifies the TGF-β pathway as a novel putative epileptogenic signaling cascade and therapeutic target for the prevention of injury-induced epilepsy. epilepsy often develops following traumatic, ischemic, or infectious brain injury. While the electrical activity of the epileptic brain is well characterized, the mechanisms underlying epileptogenesis are poorly understood. We have recently shown that in the rat neocortex, long-lasting breakdown of the blood-brain barrier (BBB) or direct exposure of the neocortex to serum-derived albumin leads to rapid upregulation of the astrocytic marker glial fibrillary acidic protein, followed by delayed (within 4-7 day) development of an epileptic focus. We investigated the role of astrocytes in epileptogenesis in the BBB-breakdown and albumin models of epileptogenesis. We found similar, robust changes in astrocytic gene expression in the neocortex within hours following treatment with deoxycholic acid (BBB breakdown) or albumin. These changes predict reduced clearance capacity for both extracellular glutamate and potassium. Electrophysiological recordings in vitro confirmed the reduced clearance of activity-dependent accumulation of both potassium and glutamate 24 hour following exposure to albumin. We used a NEURON model to simulate the consequences of reduced astrocytic uptake of potassium and glutamate on EPSPs. The model predicted that the accumulation of glutamate is associated with frequencydependent (>100 Hz) decreased facilitation of EPSPs, while potassium accumulation leads to frequency-dependent (10-50 Hz) and NMDA-dependent synaptic facilitation. In vitro electrophysiological recordings during epileptogenesis confirmed frequency-dependent synaptic facilitation leading to seizure-like activity. Our data indicate a transcription-mediated astrocytic transformation early during epileptogenesis. We suggest that the resulting reduction in the clearance of extracellular potassium underlies frequency-dependent neuronal hyperexcitability and network synchronization. Neurosci 2009;29(32):9977-9986. Regulatory RNAs have been suggested to contribute to the control of gene expression in eukaryotes. Brain cytoplasmic (BC) RNAs are regulatory RNAs that control translation initiation. We now report that neuronal BC1 RNA plays an instrumental role in the protein-synthesis-dependent implementation of neuronal excitation-repression equilibria. BC1 repression counter-regulates translational stimulation resulting from synaptic activation of group I metabotropic glutamate receptors (mGluRs). Absence of BC1 RNA precipitates plasticity dysregulation in the form of neuronal hyperexcitability, elicited by group I mGluR-stimulated translation and signaled through the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway. Dysregulation of group I mGluR function in the absence of BC1 RNA gives rise to abnormal brain function. Cortical EEG recordings from freely moving BC1 −/− animals show that group I mGluRmediated oscillations in the γ frequency range are significantly elevated. When subjected to sensory stimulation, these animals display an acute group I mGluR-dependent propensity for convulsive seizures. Inadequate RNA control in neurons is thus causally linked to heightened group I mGluR-stimulated translation, neuronal hyperexcitability, heightened γ band oscillations, and epileptogenesis.
T here is little doubt that the blood-brain barrier (BBB) is now a recognized centerpiece of the puzzle of epileptogenesis. After initial descriptive studies, the field has rapidly evolved and two main concepts have emerged: 1) BBB disruption can induce "acute seizures" in rodents and human subjects, and systemic pilocarpine administration in rodents causes status epilepticus by opening the BBB (1-4); and 2) "Delayed epileptogenesis" is mediated by an interplay involving endothelia-astrocyte signaling (perhaps, triggered by BBB disruption) (5) . The latter concept is the focus of the papers by Cacheaux et al. and David et al. The immediate development of seizures after acute BBB disruption is likely to depend on rapid (minutes) diffusion of serum contents across a leaky BBB or by rapid (tens of minutes) activation of the immune system, which can be prevented by inhibition of serum interleukin-1 (IL-1) β signaling or leukocyte-endothelial interactions (1, 2) . The time interval of the experimental epileptogenesis models (several hours in vitro and 4 days in vivo) suggests a transcription-mediated mechanism.
The process described in the papers highlighted here deals with delayed epileptogenesis and shows that in addition to Epilepsy Currents, Vol. 10, No. 3 (May/June) 2010 pp. 67-69 Wiley Periodicals, Inc. C American Epilepsy Society peripheral inflammatory markers, new targets have been unveiled. Both studies have elegantly shown that the molecular effector that links BBB failure to astrocytic dysfunction is albumin acting on a specific receptor: transforming growth factor-β (TGF-β). The experimental design is simple yet remarkable for its reproducibility. In the paper by Cacheaux and colleagues, an in vivo model of progressive BBB disruption is obtained by deoxycholic acid applied to the cortex, which results in the gradual development of hypersynchronous neuronal epileptiform activity. The in vitro model, used in the study by David and colleagues, is based on the direct application of albumin on brain slices; the procedure also causes spontaneous and evoked neuronal discharges that are similar to the EEG recordings obtained in vivo. The albumin and deoxycholic acid mechanisms proposed by Cacheaux et al. and David et al., respectively, may both be downstream effectors of early ictal events, such as inflammatory activation of vascular adhesion molecules or increased serum IL1-β (1, 2) .
There are two significant features of these models: the similarities of outcomes in vivo and in vitro and the interchangeability of triggers (deoxycholic acid or albumin). In fact, both models and both agents implicate the same, specific glial receptor, TGF-β, as mentioned. Once they established these experimental outcomes, the authors used state-of-art cDNA array methods with two goals: 1) to describe the pathways downstream of TGF-β signaling (Cacheaux et al.), and 2) to construct a computer model describing the electrophysiological and functional changes that underlie the hyperexcitable state measured after exposure to BBB disruptors or albumin (David et al.). The results unveil a novel set of genes that mediate TGF-β actions and a mechanism of neuronal hyperexcitability that results from altered glial management of extracellular potassium ([K + ] out ) and the neurotransmitter, glutamate. The two processes are linked by a common thread: a glial resting membrane potential in which potassium influx is favored by a negative astrocytic membrane potential and glutamate uptake is driven by a sodium gradient.
The evidence that blockade of potassium uptake can promote synchronization and seizure-like activity in brain slices is not novel (6) , and the concept of potassium buffering by astrocytes and other glial subtypes is equally well established (1) . What, then, is the novelty of these two studies? The original work was performed by using nonphysiological blockers of [K + ] out uptake. In particular, the ion cesium was found not only to depolarize glial cells but also to reduce potassium fluxes into the glial syncytium. The subsequent quest for endogenous inward rectifier potassium-channel (K ir ) blockers has revealed only a few viable candidates, albumin being one of the most appealing for the reasons outlined in the manuscripts reviewed here. In addition, the description of a downstream cascade of extracellular events, provided by the authors, is clearly a first.
In Cacheaux et al., the authors report that TGF-β signaling is sufficient to induce epileptiform activity and that it is the mechanism by which albumin causes delayed-onset seizures. In addition, the accompanying paper by David et al. shows that an early and prominent change in astrocytic gene expression is an important early feature of BBB breakdown and albumininduced epileptogenesis. This finding indirectly but convincingly shows that the endogenous effector of reduced [K + ] out regulation after BBB disruption is indeed albumin acting on TGF-β receptors. By a combination of routine gene chip analysis and historical data from the literature, the authors were able to construct a computer model that recapitulates some of the neuronal changes that one would predict to occur when glial function is affected. Most of the features are consistent with what basic scientists would expect to see in a model of early epileptogenesis. Thus, the model is likely to become a useful tool to study how various interventions, such as BBB disruption, affect synaptic transmission.
There are a number of future developments that may result from this model and, in general, from albumin as a pathological agent responsible for post-BBB disruption epileptogenesis. However, first there is a need for a cross comparison with data sets obtained from other models of epilepsy in which BBB disruption is the event that triggers the initial seizure. For example, both osmotic BBB disruption (4) and pilocarpine (3,7) may act by interrupting normal potassium homeostasis. A cross comparison would add impetus to a synergistic research effort that might link different models of seizures and epileptogenesis to meaningful mechanisms of clinical relevance. It is well established that BBB disruption, as seen after traumatic brain injury, inflammation or fever, and cerebrovascular accidents, is a chief epidemiologic trigger of both acute seizures and delayed epileptogenesis. Opening of the BBB caused by yet unknown inflammatory triggers or by infection, stroke, and transient ischemic attacks might set the process in motion. Such events might cause a first seizure (perhaps directly triggered by extravasating potassium ions, as suggested by David et al. and Janigro et al. (6) among others) that is accompanied by albumin leakage. BBB leakage has been demonstrated in rodent models (2) as well as in human tissue (8) . After the initial event, the cascade described in these papers will transform an initial ictal event into an epileptogenic process that may results in spontaneous seizures.
There are two considerations that may slightly dampen enthusiasm for these papers. First, several investigators have seen abundant albumin uptake by neurons and not by glia (9) . The relevance of this seemingly conflicting finding, given that different experimental approaches were used, is unclear. In addition, it has not yet been shown that TGF-β receptors in human brain are located in proximity to regions of BBB leakage. If this turns out to be the case, as is expected given the results in rodents, it will become important to understand if this mechanism is unique to epileptic brain or a feature common across the broad spectrum of neurological diseases that are characterized by a leaky BBB (10) . linked to juvenile myoclonic epilepsy (JME), one of the most frequent forms of idiopathic generalized epilepsies. JME is associated with subtle alterations of cortical and subcortical architecture, but the underlying pathological mechanism remains unknown. We found that EFHC1 is a microtubule-associated protein involved in the regulation of cell division. In vitro, EFHC1 loss of function disrupted mitotic spindle organization, impaired M-phase progression, induced microtubule bundling, and increased apoptosis. EFHC1 impairment in the rat developing neocortex by ex vivo and in utero electroporation caused a marked disruption of radial migration. We found that this effect was a result of cortical progenitors failing to exit the cell cycle and defects in the radial glia scaffold organization and in the locomotion of postmitotic neurons. Therefore, we propose that EFHC1 is a regulator of cell division and neuronal migration during cortical development and that disruption of its functions leads to JME.
COMMENTARY
T he concept of idiopathic epilepsies has undergone dramatic revisions in recent years. According to its Greek origins, idios means "one's own" or "pertaining to one's self," implying that an idiopathic disease represents a primary, isolated disorder without any other cause or associated diseases. Alternatively, the word idiopathic is often used simply to mean "of unknown cause." Recent insights into the molecular genet-ics and pathophysiology of idiopathic epilepsies have threatened to make the term "idiopathic" obsolete.
Ever since idiopathic epilepsy syndromes were described, based on characteristic clinical and electroencephalographic features, a genetic etiology was suspected because of occasional familial groupings. Over the past decade, a number of genes have been identified as causing various idiopathic epilepsies, especially in cases with defined familial patterns of inheritance. Most of these genes encode for ion channels, such as voltagegated sodium or potassium channels, or GABA-receptor channels. Thus, these disorders fall into an emerging group, classified as channelopathies. Although most identified genes causing idiopathic epilepsy syndromes encode ion channels, pathogenic genes have not yet been found in the majority of cases of idiopathic epilepsies, especially sporadic cases. Furthermore, a few genes have been discovered that produce nonchannel proteins.
Juvenile myoclonic epilepsy (JME) represents one of the most common types of idiopathic epilepsy. JME is a generalized epilepsy, classically characterized by onset during adolescence, the presence of myoclonic seizures, variable frequency of generalized tonic-clonic and absence seizures, and a 4-6 Hz generalized spike-or polyspike-wave pattern on EEG. Although JME is one of the prototypical idiopathic epilepsies, detailed pathological and radiographic studies have previously suggested that subtle anatomical abnormalities may contribute to the pathophysiology of this disease. In particular, postmortem pathological analysis of the brains of presumed JME patients demonstrate dysmorphic neurons and subtle abnormalities in cortical architecture, consistent with microdysgenesis (1). Furthermore, quantitative MRI has found increases in cortical gray matter volume in JME patients (2, 3) . Consistent with the initial discovery of genes causing other idiopathic epilepsies, the first couple of genes associated with JME involved mutations in genes for ion channels, such as the GABA A receptor (4). Shortly thereafter, however, mutations in a novel, nonchannel gene, EFHC1, were identified as the cause of some cases of familial JME (5) . Subsequent studies suggest that EFHC1 mutations are currently the most commonly identified cause of JME, although most cases of JME still have no identified cause (6).
Myoclonin 1, or EF-hand domain containing protein 1 (EFHC1), is a nonchannel protein with an EF-hand domain possessing calcium-binding functions. Initial studies of EFHC1 function indicated that this protein promotes apoptosis by activation of R-type calcium channels. Mutations in the EFHC1 gene inhibited apoptosis, suggesting that excessive neuronal survival and density in cortex could account for structural abnormalities in JME (5) . Interestingly, other studies reported that EFHC1 is a homolog of an axonemal protein found in motile cilia and flagella (7) . While these novel findings suggested that EFHC1 might interact with microtubule-based cytoskeletal elements, another study found that EFHC1 was specifically associated with mitotic spindles during cell division in cultured cell lines (8) . Overall, these observations raise the tantalizing possibility that EFHC1 gene mutations might cause disruptions in cell division and survival during early corticogenesis, with resultant developmental brain abnormalities leading to epilepsy in affected JME patients.
The recent study by de Nijs et al. more directly addresses the potential role of EFHC1 in cortical development. Extending previous work documenting the association of EFHC1 with mitotic spindles (7) , the investigators first demonstrated that EFHC1 represents a novel microtubule-associated protein, or MAP, that directly binds α-tubulin and is required for normal mitotic spindle organization in HEK293-cultured cells in vitro. Furthermore, in potential conflict with a previous study (5) , loss of function of EFHC1 caused an increase, not decrease, in apoptosis. Most impressively, the authors extended the functional analysis of EFHC1 to the brain in situ, utilizing technically demanding ex vivo and in utero electroporation of EFHC1 short hairpin RNA (shRNA) to inactivate EFHC1 function in the developing rat brain. With these methods, they demonstrated that focal inactivation of EFHC1 disrupts several processes of normal embryonic cortical development. EFHC1 inactivation interfered with mitosis and cell cycle exit of cortical progenitors in the ventricular zone. Furthermore, the normal radial migration of progenitor cells and projection neurons out of the ventricular zone, the organization of radial glia scaffolding, and subsequent locomotion of postmitotic neurons to the cortical plate were all impaired by EFHC1 inactivation.
Overall, these novel findings indicate that EFHC1 mutations may interfere with multiple steps in embryonic cortical development. These effects are most likely primarily related to a disruption of normal interactions of EFHC1 with mitotic spindles, causing an arrest of cortical progenitor cells in the ventricular zone and subsequent downstream inhibition of neuronal migration. In addition, migration of postmitotic neurons might also be impaired as a result of direct effects of the dysfunctional microtubule-associated EFHC1 protein on microtubule-based locomotion. Thus, this study supports the intriguing idea that an idiopathic epilepsy-JME-might actually be caused by a subtle malformation of cortical development.
Although there is some merit and previous data to support this paradigm-shifting idea of JME as a type of cortical malformation (1-3), there also are several possible discrepancies and paradoxes among different studies on EFHC1 function. First, while the present study concluded that EFHC1 inactivation leads to increased apoptosis, a previous study found the opposite (5) . A decrease, not increase, in apoptosis might be more consistent with the radiographic findings of increased cortical gray matter volume in JME patients (2, 3) . Second, a recently created Efch1-/-null mouse exhibits increased seizure susceptibility, enlarged ventricles, and reduced hippocampal size (9) . However, no grossly apparent structural abnormalities of neocortex were reported in these mice, in contrast to what might be predicted by the impaired mechanisms of cortical development demonstrated in the present study. Similarly, the reported effects of EFHC1 inactivation on progenitor cell turnover and neuronal migration might be expected to lead to a dramatic cortical phenotype in humans, such as lissencephaly or doublecortex resulting from LIS1 or DCX/DCLK mutations, which also have microtubule-associated protein-like functions. However, the available neuropathological studies of potential relevance to JME, reveal much more subtle cortical abnormalities, consisting of microdysgenesis (1) . Finally, as EFHC1 mutations probably account for only a minority of cases of all JME (10), other pathophysiological mechanisms likely also are important in generating the phenotype of JME. Thus, while the present study is exciting and provocative in supporting a novel pathophysiology of JME, additional mechanistic studies of EFHC1 function as well as detailed clinicopathological studies of JME patients are needed to determine whether idiopathic JME is actually caused by a malformation of cortical development.
by Michael Wong, MD, PhD needed, ionotropic glutamate receptors take charge and mediate the effect very efficiently. For more enduring responses, long-lasting modification of neuronal excitability and synaptic plasticity are necessary. In these cases, metabotropic glutamate receptors (mGluRs) are very useful for generating an intracellular second-messenger cascade of events that can culminate in the plastic changes required. Group I mGluRs, in particular, have been shown to serve important roles in synaptic plasticity processes that underlie both long-term potentiation and long-term depression. However, excessive activation of group I mGluRs can result in a long-lasting enhancement of network excitability, potentially leading to epileptogenesis (1) . These mGluR-mediated plasticity processes are protein synthesis-dependent (2) . How does the system allow for localized plasticity to occur without always resulting in the pathologic network hyperexcitability underlying epilepsy? It appears that there are endogenous regulators in place that, in essence, put the brakes on the induced protein synthesis and thus, suppress excessive excitation. One such regulator is the fragile X mental retardation protein (FMRP), as discussed in a 2009 Epilepsy Currents commentary (3). The recent paper by Zhong and colleagues reveals yet another potent suppressor of this mGluR-induced pathway: brain cytoplasmic 1 RNA (BC1 RNA).
RNA was once, in the not-so-distant past, believed to serve primarily as a means to convert genetic code into proteins. Work done in recent years, however, has brought a wealth of information regarding the previously underappreciated roles of RNA. Specifically, small non-protein-coding segments of RNA have been found to be critical to higher organisms in the regulation of numerous cellular functions, such as helping to determine when and where specific genes are expressed and restricting the translation of certain proteins, thereby regulating synaptic plasticity. It is estimated that close to 98% of the human genome may code for these non-protein-coding RNAs (4) .
What determines the impact of a given RNA on cellular function? How can a tiny bit of RNA modulate plasticity processes? Oftentimes, the influence of RNA on cellular function is highly dependent on location, location, location. (5) . The dendritic colocalization of small RNAs and transitional machinery serve to compartmentalize the neuron, creating microdomains in which concentrations of key regulators and proteins can fluctuate in response to synaptic inputs and have a localized impact. Such localized modifications turn out to be essential for neuronal development in the immature nervous system as well as for the normal functioning of fully differentiated neurons and glia.
BC1 RNA is a brain-specific regulatory RNA whose expression is primarily localized to dendrites, where it serves to suppress the synthesis of certain proteins at the synapse by interfering with translation initiation (6) . When scientists de-veloped knockout mice to determine the significance of BC1 RNA, they reported that the mice were not only viable but at first glance appeared healthy (7) . Subsequent studies revealed, however, that the animals were more anxious and displayed a diminished tendency to explore their surroundings (8) . The current study by Zhong and colleague delves deeper into the physiologic impact of the absence of BC1 RNA.
Zhong and colleagues conducted a beautiful series of experiments using the BC1 RNA knockout mouse strain. The investigators examined both the cellular and network impact of the absence of BC1, combining in vitro and in vivo electrophysiological and molecular approaches and, most importantly, demonstrating the ability to reverse each of the observed abnormalities, thereby causally relating the deficient RNA, the enhanced group I mGluR physiologic responses, and the resultant phenotype. Comparing wild-type and mutant mice, they first demonstrated that mGluR-driven synthesis of synaptic proteins is enhanced in the BC1 knockout mouse. This finding correlated with an enhanced expression of ictal-length discharges that were dependent on group I mGluR activation and whose expression could be prevented with protein synthesis inhibitors. Functionally, this enhanced expression of discharges translated to a lowered seizure threshold that was manifested by the presence of audiogenic seizures, which were fatal in 23% of the animals. Here, too, the seizures could be prevented through the use of either group I mGluR antagonists or protein synthesis inhibitor. Finally, in nonconvulsing animals, EEG recordings revealed an increased presence of mGluR-dependent γ oscillations that were similarly sensitive to mGluR5 antagonist and to protein synthesis inhibitor (9) .
These data reveal the delicate balance that exists between group I mGluR-mediated neuronal excitation and the protein-synthesis-dependent network plasticity that underlies the epileptogenic process. Activation of group I mGluRs drives an increase in protein synthesis, and if it is left unchecked, persistent ictal discharges may be expressed by the hippocampal network, leading to epileptogenesis (2) . Fortunately, there are built-in roadblocks that titrate this effect and allow for some degree of excitation to come through without culminating in epilepsy. BC1 RNA is upregulated during times of increased activity (10), suggesting a compensatory effect that enhances its protective role during potentially epileptogenic events. In the absence of BC1 RNA, deficient endogenous regulation of group I mGluR-driven protein synthesis leads to epileptogenesis. The strength of this study by Zhong and colleagues is confirmation of the causative correlation between protein synthesis and the epileptic phenotype through the use of both protein synthesis inhibitors and mGluR antagonists.
A greater understanding the second-messenger pathways and endogenous control mechanisms involved in the epileptogenic process provides insights on the wide range of responses evoked by similar insults (e.g., head trauma). Genetic variability in FMRP, BC1 RNA, or group I mGluRs among various individuals could potentially result in different levels of excitatory responses to similar provocations, and if the net excitatory response is enhanced, the outcome may be epilepsy. If so, targeting these pathways may provide novel therapeutic avenues for those patients whose seizures are mGluR-dependent.
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